Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
83.95%
operating margin TTM
80.79%
revenue TTM
21.28 Million
revenue per share TTM
0.11$
valuation ratios | |
|---|---|
| pe ratio | 4.95 |
| peg ratio | 0.00 |
| price to book ratio | 3.06 |
| price to sales ratio | 4.24 |
| enterprise value multiple | 5.33 |
| price fair value | 3.06 |
profitability ratios | |
|---|---|
| gross profit margin | 99.98% |
| operating profit margin | 80.79% |
| pretax profit margin | 83.95% |
| net profit margin | 83.95% |
| return on assets | 57.99% |
| return on equity | 129.32% |
| return on capital employed | 56.85% |
liquidity ratios | |
|---|---|
| current ratio | 54.26 |
| quick ratio | 54.26 |
| cash ratio | 4.64 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 2.50 |
| days of payables outstanding | 16,170.61 |
| cash conversion cycle | -16,168.10 |
| receivables turnover | 145.92 |
| payables turnover | 0.02 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 1,798.47 |
| cash flow to debt ratio | -54.45 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.18 |
| cash per share | 0.49 |
| operating cash flow per share | -0.18 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -54.45 |
| short term coverage ratios | -54.45 |
| capital expenditure coverage ratio | -8,589,000.00 |
Frequently Asked Questions
When was the last time Arbutus Biopharma Corporation (NASDAQ:ABUS) reported earnings?
Arbutus Biopharma Corporation (ABUS) published its most recent earnings results on 13-05-2026.
What is Arbutus Biopharma Corporation's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Arbutus Biopharma Corporation (NASDAQ:ABUS)'s trailing twelve months ROE is 129.32%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Arbutus Biopharma Corporation (ABUS) currently has a ROA of 57.99%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ABUS's net profit margin stand at?
ABUS reported a profit margin of 83.95% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ABUS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 54.26 in the most recent quarter. The quick ratio stood at 54.26, with a Debt/Eq ratio of 0.00.